Impact of the IRA on Oncology Patient Care features an interview with Dr. Barbara L. McAneny, MD, FASCO, MACP Former President for the American Medical Association and the New Mexico Medical Society (NMMS); and currently CEO, New Mexico Cancer Center.
With Dr. Steve Potts CEO, Anticipate Bioscience.
Impact of the IRA on Oncology Patient Care was recorded on the 26th of May 2023
The Inflation Reduction Act of 2022 (the IRA)
On August 16, 2022, President Biden signed into law P.L. 117-169, a budget reconciliation measure known as the Inflation Reduction Act (the Act). The Act makes widereaching changes to Medicare prescription drug coverage and more targeted changes to Medicaid, the State
Children’s Health Insurance Coverage Program (CHIP), and private health insurance. (Source)
Following the passage of the IRA, The White House published fact sheets outlining how the act will benefit the people of the United States.
In October of 2022, AZBio hosted a conversation looking at what comes next featuring a conversation related to benefits of the IRA and concerns related to the unintended consequences with AZBio Board Member Steve Potts, PhD, MBA. Dr. Potts has worked in the biopharma industry since 1999 and has had experience in a wide range of areas, including product development, sales, marketing, and general management. He has a proven track record of success, with 3 of his last 4 companies having returned investors a minimum of 8x (800%) on their investments. He currently serves as the founding CEO of Anticipate Biosciences.
Since that time, more conversations with key opinion leaders (KOLs) have focused on this important policy discussion.
The Impact of the IRA on Oncology Patient Care features an interview with Dr. Barbara L. McAneny, MD, FASCO, MACP Former President for the American Medical Association and the New Mexico Medical Society (NMMS); and currently CEO, New Mexico Cancer Center with Dr. Steve Potts.
Dr. Barbara L. McAneny MD, FASCO, MACP is the Former President for the American Medical Association (2018-2019) and the New Mexico Medical Society (NMMS). Dr. McAneny is CEO and one of the two founding partners of New Mexico Cancer Center, an independent, multi-disciplinary practice operated by NM Oncology Hematology Consultants Ltd., providing integrated, comprehensive cancer care including chemotherapy, radiation therapy, imaging, pharmacy, and after-hours and weekend care, at multiple sites in New Mexico, including underserved rural areas. NMCC participates in the National Cancer Care Alliance, a recently founded national collaborative spearheaded by Dr. McAneny.
The Impact of the IRA on Oncology Patient Care was recorded on the 26th of May 2023 by Dr. Steve Potts, CEO, Anticipate Bioscience.
Other KOL discussions on this topic:
- The IRA: How Public Policy Impacts Innovation (video) Dr. Steve Potts with Dr. Rafael Fonseca (May 12, 2023)
-
Preserving the biotech social contract – we should all be pitching in by Dr. Steve Potts (May 1, 2023)
-
The IRA is now law. What comes next? (video) Joan Koerber-Walker, president & CEO, AZBio with Dr. Steve Potts (October 19, 2022)
-
Saving money for Medicare by abandoning new drugs for Medicare patients by Dr. Steve Potts (September 21, 2022)
-
Industry Leaders Weigh In on the Inflation Reduction Act (August 7, 2022)